Vietnam Oral Anti-Diabetic Drug Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 156.21 Million |
| Market Size (2029) | USD 195.32 Million |
| CAGR (2024 - 2029) | 4.00 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Vietnam Oral Anti-Diabetic Drug Market Analysis
The Vietnam Oral Anti-Diabetic Drug Market size is estimated at USD 156.21 million in 2024, and is expected to reach USD 195.32 million by 2029, growing at a CAGR of greater than 4% during the forecast period (2024-2029).
According to the Ministry of Health (MOH), Vietnam saw four waves of the COVID-19 pandemic. Coronavirus-2, which causes SARS-CoV-2, was identified as the source of COVID-19 (coronavirus disease), a highly contagious viral illness. A SARS-CoV-2 receptor in humans is angiotensin-converting enzyme 2 (ACE2). Angiotensin-converting enzyme (ACE) inhibitors must thus be taken with caution in those with diabetes. Diabetes substantially increased COVID-19 severity and death compared to non-diabetics. As a result, people with diabetes must be careful during the COVID-19 outbreak.
Diabetes mellitus (DM) has quickly become a major public health problem in Vietnam. Although the incidence of diabetes has been researched in northern and southern Vietnam, little information is known about the country's middle area. As a result, the purpose of this research was to assess the prevalence of undiagnosed diabetes and prediabetes, as well as its risk factors, in a mixed urban-rural context. The ministry started a program to strengthen the diagnosis of diabetes and the treatment competence of medical professionals in caring for diabetic patients in Vietnam.
Vietnam Oral Anti-Diabetic Drug Market Trends
Sulfonylureas Segment Occupied the Highest Market Share in the Vietnam Oral Anti-Diabetic Drugs Market in the current year.
Regarding revenue, the Sulfonylureas segment is anticipated to lead the Indonesia Oral Anti-Diabetic Drugs Market and post a CAGR of over 1% during the forecast year. Among the several Oral anti-diabetes drugs available, sulfonylureas (SUs) constitute one of the vital pharmacotherapeutic agents in managing T2DM.
When Janbon et al. noticed that certain sulfonamides caused hypoglycemia in experimental animals, they discovered sulfonylureas. Carbutamide (1-butyl-3-sulfonylurea) was created as a result of this finding. The first sulfonylurea used to treat diabetes was carbamide, which was later taken off the market due to its harmful effects on bone marrow.
Various sulfonylureas were available by the 1960s, often divided into two categories (or generations). Second-generation sulfonylureas like gliclazide, glipizide, glibenclamide, and glimepiride are presently in use, although first-generation medications like tolbutamide and chlorpropamide are no longer. Despite variations in absorption, metabolism, and dosage, second-generation drugs are similarly efficient at lowering blood glucose levels. When diet and exercise alone are insufficient to maintain a healthy blood sugar level, persons with type 2 diabetes frequently turn to drugs as their first line of treatment.
To treat type 2 diabetes mellitus, a wide range of anti-diabetic medications are now accessible. These include sulfonylureas, glinides, thiazolidinediones, biguanides, and -glucosidase inhibitors. Drugs linked to incretins have recently been created, including glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. Despite the abundance of anti-diabetic medications on the market, sulfonylureas are the most popular medication for treating people with type 2 diabetes.
The increasing Diabetes Population in Vietnam is driving the market.
Obesity, nutritional changes, and other cultural shifts are all linked to diabetes, a developing issue in Vietnam. More study is required to understand this healthcare issue further and provide focused solutions.
As people age, issues are more common. The aging population that Vietnam will soon experience and the prolonged lifespans of diabetics brought on by more effective treatment choices are anticipated to result in higher costs.
According to research on the financial toll of diabetes in the US, expenses have increased despite efforts to cut back on avoidable hospitalization. This shows that to change the trend or even slow the rise in the cost of diabetes, present treatments in Vietnam must be increased. However, given that Vietnam is also dealing with other non-communicable illnesses that continue to compete for resources in the already constrained public healthcare budget, it is impossible to increase budget allocation and resources to address the issue considerably. The government should instead work to deploy its resources better. The whole budget might be affected only somewhat by a few economic decisions.
To keep diabetes under control, regular monitoring services and more potent glucose-lowering medications should be implemented at the primary care level. In Vietnam, insulin treatment is only started if the HbA1c level is below 9% and is only available at district-level or higher health institutions. The healthcare system and society are financially burdened by diabetes and its consequences, with a sizable portion of spending on addressing complications. To better manage diabetes and minimize difficulties, which might lessen the financial and health burden on the healthcare system and society, actions aimed at improving patient glycemic control should be taken.
Vietnam still maintains a low prevalence of obesity, despite a significant rise over the previous ten years, especially the last five years. These gains coincided with continuous malnutrition increases, confirming the coexisting problems of over- and undernutrition in Vietnam and other developing countries. Additionally, the majority of those with T2D have a BMI of 23 kg/m2. Still, their adiposity has grown, as seen by an increase in WHR and linked to chronic overconsumption of foods with a high glycemic index.
Vietnam Oral Anti-Diabetic Drug Industry Overview
Vietnam Oral Anti-Diabetic Drug Market is consolidated, with a few major manufacturers like Eli Lilly, AstraZeneca, Sanofi, and Janssen Pharmaceuticals having a global market presence, while the remaining manufacturers are confined to the other local or regional markets. Companies are focusing on innovations in diabetes drugs.
Vietnam Oral Anti-Diabetic Drug Market Leaders
-
Astrazeneca
-
Astellas
-
Janssen
-
Eli Lilly
-
Sanofi
*Disclaimer: Major Players sorted in no particular order
Vietnam Oral Anti-Diabetic Drug Market News
- January 2024: Lupin gets USFDA approval to market generic medication to treat diabetes.
- November 2022: A pre-post study was Conducted which aimed to evaluate the impact of a peer-based club intervention to improve self-management among people living with T2D in two rural communities in Vietnam.
Vietnam Oral Anti-Diabetic Drug Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.3 Market Restraints
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 Oral Anti-diabetic drugs
- 5.1.1 Biguanides
- 5.1.1.1 Metformin
- 5.1.2 Alpha-Glucosidase Inhibitors
- 5.1.2.1 Alpha-Glucosidase Inhibitors
- 5.1.3 Dopamine D2 receptor agonist
- 5.1.3.1 Bromocriptin
- 5.1.4 SGLT-2 inhibitors
- 5.1.4.1 Invokana (Canagliflozin)
- 5.1.4.2 Jardiance (Empagliflozin)
- 5.1.4.3 Farxiga/Forxiga (Dapagliflozin)
- 5.1.4.4 Suglat (Ipragliflozin)
- 5.1.5 DPP-4 inhibitors
- 5.1.5.1 Onglyza (Saxagliptin)
- 5.1.5.2 Tradjenta (Linagliptin)
- 5.1.5.3 Vipidia/Nesina(Alogliptin)
- 5.1.5.4 Galvus (Vildagliptin)
- 5.1.6 Sulfonylureas
- 5.1.6.1 Sulfonylureas
- 5.1.7 Meglitinides
- 5.1.7.1 Meglitinides
6. MARKET INDICATORS
- 6.1 Type-1 Diabetic Population
- 6.2 Type-2 Diabetic Population
7. COMPETITIVE LANDSCAPE
-
7.1 COMPANY PROFILES
- 7.1.1 Takeda
- 7.1.2 Novo Nordisk
- 7.1.3 Pfizer
- 7.1.4 Eli Lilly
- 7.1.5 Janssen Pharmaceuticals
- 7.1.6 Astellas
- 7.1.7 Boehringer Ingelheim
- 7.1.8 Merck And Co.
- 7.1.9 AstraZeneca
- 7.1.10 Bristol Myers Squibb
- 7.1.11 Novartis
- 7.1.12 Sanofi
- *List Not Exhaustive
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityVietnam Oral Anti-Diabetic Drug Industry Segmentation
Orally administered antihyperglycemic drugs reduce blood glucose levels. They are often used in type 2 diabetes care. Vietnam's oral anti-diabetic drug market is segmented into drugs. The report offers the market size in value terms in USD and Volume in terms of Unit for all the abovementioned segments.
| Oral Anti-diabetic drugs | Biguanides | Metformin |
| Oral Anti-diabetic drugs | Alpha-Glucosidase Inhibitors | Alpha-Glucosidase Inhibitors |
| Oral Anti-diabetic drugs | Dopamine D2 receptor agonist | Bromocriptin |
| Oral Anti-diabetic drugs | SGLT-2 inhibitors | Invokana (Canagliflozin) |
| Jardiance (Empagliflozin) | ||
| Farxiga/Forxiga (Dapagliflozin) | ||
| Suglat (Ipragliflozin) | ||
| Oral Anti-diabetic drugs | DPP-4 inhibitors | Onglyza (Saxagliptin) |
| Tradjenta (Linagliptin) | ||
| Vipidia/Nesina(Alogliptin) | ||
| Galvus (Vildagliptin) | ||
| Oral Anti-diabetic drugs | Sulfonylureas | Sulfonylureas |
| Oral Anti-diabetic drugs | Meglitinides | Meglitinides |
Vietnam Oral Anti-Diabetic Drug Market Research Faqs
How big is the Vietnam Oral Anti-Diabetic Drug Market?
The Vietnam Oral Anti-Diabetic Drug Market size is expected to reach USD 156.21 million in 2024 and grow at a CAGR of greater than 4% to reach USD 195.32 million by 2029.
What is the current Vietnam Oral Anti-Diabetic Drug Market size?
In 2024, the Vietnam Oral Anti-Diabetic Drug Market size is expected to reach USD 156.21 million.
Who are the key players in Vietnam Oral Anti-Diabetic Drug Market?
Astrazeneca, Astellas, Janssen, Eli Lilly and Sanofi are the major companies operating in the Vietnam Oral Anti-Diabetic Drug Market.
What years does this Vietnam Oral Anti-Diabetic Drug Market cover, and what was the market size in 2023?
In 2023, the Vietnam Oral Anti-Diabetic Drug Market size was estimated at USD 149.96 million. The report covers the Vietnam Oral Anti-Diabetic Drug Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Vietnam Oral Anti-Diabetic Drug Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Vietnam Oral Anti-Diabetic Drug Industry Report
Statistics for the 2024 Vietnam Oral Anti-Diabetic Drug market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Vietnam Oral Anti-Diabetic Drug analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
